Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline <i>MMS22L</i> F722fs Mutation
Although limited by its retrospective design and small cohort size, this series suggests the potential for exceptional outcomes in F722fs mutation carriers diagnosed with prostate cancer, despite the aggressive disease features and lack of treatment with PARPi. The findings also suggest that prostate cancer patients with this mutation may respond well to standard systemic treatments.
Authors
- В. Даниэльс (ORCID: https://orcid.org/0009-0006-4263-9007)
- Tamara L. Lotan (ORCID: https://orcid.org/0000-0002-0494-9067)
- Walsh Pc
- Catherine Handy Marshall (ORCID: https://orcid.org/0000-0002-2653-4110)
- Mayuko Kanayama (ORCID: https://orcid.org/0000-0002-1947-6311)
- Jianfeng Xu (ORCID: https://orcid.org/0000-0001-5592-3265)
- Jia Li (ORCID: https://orcid.org/0000-0003-0307-3814)
- Alex Brame
- William B. Isaacs
- Marta Gielzak
- Misop Han
- Jun Luo
- Mario A. Eisenberger
Institutions
- Brigham and Women's Hospital (US)
- NorthShore University HealthSystem (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- University of Chicago (US)
Publication Details
- Journal
- The Prostate
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1002/pros.70133
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Prostate Cancer Foundation
- Ambrose Monell Foundation
- National Institutes of Health